tenofovir (TDF)
Jump to navigation
Jump to search
Indications
- HIV/AIDS (FDA approved 2001)
- 1% tenofovir gel used intravaginally before & after sex reduces incidence of
- chronic hepatitis B
Dosage
1% tenofovir gel
Storage
- store in orginal container
- original container (tabs, oral powder) has a desiccant[11]
Monitor
Adverse effects
- reportedly fewer adverse effects that with other nucleoside reverse transcriptase inhibitors
- tenofovir associated with fewer cardiovascular deaths than avacavir[5]
- nephrotoxicity* (tubulointerstitial disease) due to mitochondrial damage within renal tubular cells
- associated with tenofovir disoproxil fumarate*
- renal tubular acidosis type 2
- glycosuria despite normal serum glucose (Fanconi syndrome)
- mild proteinuria
- discontinue tenofovir
- recovery of renal function within weeks to months
- chronic renal failure possible
- Fanconi syndrome[8]
- decreased bone mineral density*
- nausea[8]
* novel formulation tenofovir alafenamide, component of Genvoya may be associated with less nephrotoxicity & less effects on bone mineral density[13]
Drug interactions
- reportedly fewer drug interactions that with other nucleoside reverse transcriptase inhibitors
Laboratory
Mechanism of action
- nucleoside reverse transcriptase inhibitor
- reportedly less likely than other nucleoside reverse transcriptase inhibitors to develop resistance
- report of effectiveness in resistant HIV[2]
- has activity against hepatitis B virus[8]
Clinical trials
- VOICE trial: tenofovir gel did no better than placebo in preventing sexual transmission of HIV in women[7]
Manufacturer: Gilead Sciences
More general terms
More specific terms
Additional terms
Component of
- lamivudine/tenofovir
- doravirine/lamivudine/tenofovir
- bictegravir/emtricitabine/tenofovir (Biktarvy)
- cobicistat/elvitegravir/emtricitabine/tenofovir (Quad, Stribild, Genvoya)
- emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF, TAF/FTC/RPV, Complera, Odefsey)
- emtricitabine/tenofovir (Truvada, TDF/FTC, Descovy)
- efavirenz/emtricitabine/tenofovir (Atripla)
References
- ↑ Prescriber's Letter 8(12):70 2001
- ↑ 2.0 2.1 Journal Watch 23(20):158, 2003 Squires K et al, Ann Intern Med 139(Sep 2):313, 2003
- ↑ Department of Veterans Affairs, VA National Formulary
- ↑ Centers for Disease Control CDC trials of daily oral tenofovir for preventing HIV infection http://www.cdc.gov/hiv/PUBS/TenofovirFactSheet.htm
- ↑ 5.0 5.1 Martin A et al Simplification of antiretroviral therapy with t enofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial. Clin Infect Dis 2009 Nov 15; 49:1591. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19842973
- ↑ 6.0 6.1 Abdool KQ et al, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010 Jul 19 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20643915 <Internet> http://www.sciencemag.org/cgi/content/abstract/science.1193748v1
- ↑ 7.0 7.1 Sax PE HIV and ID Observations Journal Watch Blogs Massachusetts Medical Society http://blogs.jwatch.org
- ↑ 8.0 8.1 8.2 8.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18. American College of Physicians, Philadelphia 2012, 2015, 2018.
- ↑ Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009 Oct;5(10):563-73 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19776778
- ↑ 10.0 10.1 Zuger A Use of Antiretroviral Drugs in Pregnancy. Physician's First Watch, April 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. AIDSinfo. Clinical Guidelines Portal. March 28, 2014. http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (corresponding NGC guideline withdrawn March 2016) - ↑ 11.0 11.1 Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 12.0 12.1 Abdool Karim SS et al Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med 2015; 373:530-539. August 6, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26244306 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1410649
- ↑ 13.0 13.1 FDA News Release. November 5, 2015 FDA approves new treatment for HIV http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471300.htm
- ↑ Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013 Oct;24(10):1519-27. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24052632 Free PMC Article
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=122767
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=124085
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=119830
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=457981
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=456325
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=456636
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=462362
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=461326